InspireMD (NSPR) Cash & Equivalents (2010 - 2025)

InspireMD has reported Cash & Equivalents for 16 years, with the latest figure at $8.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 52.74% year-over-year to $8.9 million; the trailing twelve-month figure through Dec 2025 stood at $8.9 million (down 52.74% YoY), and the FY2025 full-year result was $8.9 million, down 52.74% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $8.9 million, down from $63.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $63.4 million in Q3 2025, with the low at $3.9 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $17.1 million across 5 years, with a median of $11.8 million in 2021.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 1301.91% — and 2022, when it plunged 84.57%.
• InspireMD's Cash & Equivalents stood at $12.0 million in 2021, then tumbled by 61.41% to $4.6 million in 2022, then jumped by 108.12% to $9.6 million in 2023, then surged by 96.22% to $18.9 million in 2024, then sank by 52.74% to $8.9 million in 2025.
• The last three Cash & Equivalents figures came in at $8.9 million (Q4 2025), $63.4 million (Q3 2025), and $11.5 million (Q2 2025), per Business Quant data.